186:@0.085057:0.957873:0.109689:0.957873:0.109689:0.938882:0.085057:0.938882:0.007450:0.008591:0.008591
ADDENDUM:@0.117647:0.067543:0.201421:0.067543:0.201421:0.045457:0.117647:0.045457:0.009679:0.010295:0.010295:0.008697:0.010706:0.010295:0.010226:0.013582
39.  Robert, C. :@0.117647:0.119718:0.238069:0.119718:0.238069:0.101197:0.117647:0.101197:0.009483:0.009483:0.004088:0.003735:0.010563:0.012451:0.009961:0.010231:0.008218:0.007242:0.005852:0.004088:0.003860:0.013343:0.004088:0.003735
et al.:@0.238199:0.119718:0.273456:0.119718:0.273456:0.101006:0.238199:0.101006:0.007346:0.005727:0.003943:0.009048:0.004607:0.004586
 Improved overall survival in melanoma with combined dabrafenib and tra-:@0.273461:0.119718:0.852941:0.119718:0.852941:0.101197:0.273461:0.101197:0.003860:0.006267:0.015709:0.010065:0.006765:0.009878:0.008757:0.008280:0.010355:0.003860:0.009878:0.008759:0.008218:0.007180:0.008548:0.004897:0.004773:0.003860:0.006827:0.010376:0.007637:0.008944:0.005043:0.008944:0.008550:0.004773:0.003860:0.005105:0.010687:0.003860:0.015896:0.008135:0.004939:0.008259:0.010542:0.009857:0.015979:0.008446:0.003860:0.013385:0.004794:0.006018:0.010417:0.003860:0.008176:0.009857:0.015813:0.009836:0.005105:0.010542:0.008280:0.010355:0.003860:0.010521:0.008280:0.009836:0.007180:0.008259:0.005478:0.008218:0.010687:0.005043:0.010023:0.003860:0.008259:0.010544:0.010355:0.003860:0.005852:0.007180:0.008476:0.006848
metinib. N. Engl. J. Med. 372, 30–39 (2015).:@0.155000:0.140297:0.488082:0.140297:0.488082:0.121776:0.155000:0.121776:0.015896:0.008301:0.005852:0.005105:0.010687:0.005043:0.009317:0.004088:0.003735:0.014754:0.004088:0.003735:0.010998:0.010417:0.009025:0.004524:0.004088:0.003735:0.005105:0.004088:0.003735:0.017245:0.008280:0.010106:0.004088:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.010729:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
40.  De Roock, W. :@0.117647:0.160875:0.265479:0.160875:0.265479:0.142355:0.117647:0.142355:0.009483:0.009483:0.004088:0.003735:0.010563:0.014754:0.008218:0.004648:0.012451:0.010249:0.010251:0.007969:0.009566:0.004088:0.004648:0.015813:0.004088:0.003735
et al.:@0.266374:0.160875:0.302441:0.160875:0.302441:0.142164:0.266374:0.142164:0.007346:0.005727:0.004752:0.009048:0.004607:0.004586
 Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy :@0.302433:0.160875:0.856748:0.160875:0.856748:0.142355:0.302433:0.142355:0.004648:0.010998:0.005427:0.005261:0.008280:0.008280:0.005852:0.006973:0.004648:0.009857:0.005644:0.004648:0.013219:0.012409:0.013696:0.009193:0.004088:0.004648:0.011330:0.012407:0.013572:0.007906:0.004088:0.004648:0.014754:0.012409:0.013696:0.009193:0.004088:0.004648:0.008259:0.010542:0.010355:0.004648:0.010604:0.006599:0.013219:0.009483:0.013343:0.013572:0.004648:0.015709:0.010065:0.005956:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.004648:0.009857:0.010687:0.004648:0.006018:0.010272:0.008218:0.004648:0.008218:0.005174:0.005174:0.005112:0.008280:0.008446:0.008529:0.008840:0.003735
of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a :@0.155000:0.181454:0.856693:0.181454:0.856693:0.162933:0.155000:0.162933:0.009857:0.005644:0.003486:0.008176:0.008301:0.005603:0.010376:0.009172:0.005105:0.015979:0.008280:0.010023:0.003486:0.010148:0.004462:0.010376:0.006973:0.003486:0.007969:0.010272:0.008218:0.015896:0.009836:0.006018:0.010272:0.008218:0.007180:0.008010:0.010085:0.008840:0.003486:0.005105:0.010687:0.003486:0.007969:0.010272:0.008218:0.015896:0.009836:0.006018:0.010272:0.008218:0.007180:0.008010:0.010085:0.008840:0.006848:0.006765:0.008218:0.005831:0.007180:0.008446:0.008278:0.005647:0.009857:0.007635:0.008840:0.003486:0.015898:0.008299:0.005956:0.008446:0.006827:0.005956:0.008010:0.005852:0.005043:0.008176:0.003486:0.008176:0.009940:0.004711:0.009857:0.006765:0.008280:0.008280:0.005956:0.008550:0.004773:0.003486:0.008280:0.008259:0.010542:0.008176:0.008218:0.007388:0.004088:0.003486:0.008446:0.003735
retrospective consortium analysis. Lancet Oncol. 11, 753–762 (2010).:@0.155000:0.202033:0.683915:0.202033:0.683915:0.183512:0.155000:0.183512:0.006765:0.008301:0.005852:0.006765:0.009961:0.006827:0.010459:0.008280:0.008280:0.005852:0.005043:0.008757:0.008218:0.003735:0.008176:0.009857:0.010563:0.007157:0.009857:0.007242:0.005852:0.004794:0.010376:0.016041:0.003735:0.008259:0.010625:0.008550:0.004711:0.008840:0.006910:0.005105:0.006973:0.004088:0.003735:0.010895:0.008259:0.010542:0.008176:0.008301:0.005852:0.003735:0.014817:0.010542:0.008176:0.009940:0.004524:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
41.  Kumar-Sinha, C. & Chinnaiyan, A. M. Precision oncology in the age of integrative genomics. :@0.117647:0.222612:0.856569:0.222612:0.856569:0.204091:0.117647:0.204091:0.009483:0.009483:0.004088:0.003735:0.010563:0.012409:0.010376:0.015979:0.008259:0.006578:0.006848:0.009193:0.005105:0.010791:0.010355:0.008446:0.004088:0.003009:0.013343:0.004088:0.003009:0.014298:0.003009:0.013406:0.010417:0.005105:0.010687:0.010623:0.008259:0.005045:0.008840:0.008257:0.010687:0.004088:0.003009:0.013572:0.004088:0.003009:0.017826:0.004088:0.003009:0.010832:0.006765:0.008280:0.008176:0.005105:0.006910:0.005043:0.009857:0.010687:0.003009:0.009857:0.010544:0.008176:0.009938:0.004711:0.010044:0.009587:0.008840:0.003009:0.005105:0.010687:0.003009:0.006018:0.010272:0.008218:0.003009:0.008363:0.008778:0.008218:0.003009:0.009857:0.005644:0.003009:0.005105:0.010355:0.005644:0.008218:0.008965:0.007180:0.008010:0.005852:0.005043:0.008757:0.008218:0.003009:0.008778:0.008218:0.010542:0.009857:0.016041:0.005043:0.008176:0.006973:0.004088:0.003735
Nat. Biotechnol. 36, 46–60 (2018).:@0.155000:0.243190:0.416014:0.243190:0.416014:0.224669:0.155000:0.224669:0.014132:0.008010:0.005852:0.004088:0.003735:0.011351:0.005043:0.009836:0.005644:0.008280:0.007969:0.010417:0.010542:0.009940:0.004524:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.010729:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
42.  Burd, A. :@0.117647:0.263769:0.224746:0.263769:0.224746:0.245248:0.117647:0.245248:0.009483:0.009483:0.004088:0.003735:0.010563:0.011372:0.010376:0.006765:0.010106:0.004088:0.005644:0.013572:0.004088:0.003735
et al.:@0.226638:0.263769:0.263721:0.263769:0.263721:0.245057:0.226638:0.245057:0.007346:0.005727:0.005769:0.009048:0.004607:0.004586
 Precision medicine treatment in acute myeloid leukemia using prospective :@0.263713:0.263769:0.856753:0.263769:0.856753:0.245248:0.263713:0.245248:0.005644:0.010832:0.006765:0.008280:0.008176:0.005105:0.006910:0.005043:0.009857:0.010687:0.005644:0.015896:0.008280:0.010355:0.005043:0.008176:0.005105:0.010542:0.008218:0.005644:0.005852:0.006765:0.008446:0.008010:0.005852:0.015896:0.008218:0.010355:0.005852:0.005644:0.005105:0.010687:0.005644:0.008446:0.008280:0.010065:0.005644:0.008218:0.005644:0.015688:0.008653:0.008135:0.004711:0.009857:0.005043:0.010355:0.005644:0.004711:0.008301:0.010500:0.009338:0.008218:0.016041:0.005271:0.008446:0.005644:0.010376:0.006910:0.005105:0.010417:0.008965:0.005644:0.010065:0.006765:0.009961:0.006827:0.010459:0.008280:0.008278:0.005852:0.005043:0.008759:0.008218:0.003735
genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat. :@0.155000:0.284348:0.856612:0.284348:0.856612:0.265827:0.155000:0.265827:0.008778:0.008218:0.010542:0.009857:0.016041:0.005043:0.008176:0.005603:0.010065:0.006765:0.009857:0.005167:0.005292:0.004773:0.005105:0.010417:0.008965:0.004088:0.005603:0.005478:0.008446:0.008446:0.006910:0.005043:0.009836:0.005229:0.004773:0.004794:0.005852:0.008840:0.005603:0.008259:0.010542:0.010355:0.005603:0.010062:0.006765:0.008137:0.004773:0.005105:0.016041:0.005105:0.010623:0.008259:0.007637:0.008840:0.005603:0.008218:0.005174:0.005174:0.005112:0.008280:0.008446:0.008529:0.008840:0.005603:0.009859:0.005644:0.005603:0.006018:0.010272:0.008218:0.005603:0.011891:0.008446:0.008010:0.005852:0.005603:0.013572:0.017826:0.010563:0.005603:0.017348:0.008446:0.006827:0.005644:0.008218:0.007097:0.005603:0.010210:0.007097:0.005271:0.008550:0.004524:0.004088:0.005603:0.014132:0.008010:0.005852:0.004088:0.003735
Med. (2020) doi:10.1038/s41591-020-1089-8.:@0.155000:0.304926:0.504406:0.304926:0.504406:0.286406:0.155000:0.286406:0.017245:0.008280:0.010106:0.004088:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.003733:0.010293:0.009857:0.005105:0.004088:0.009483:0.009483:0.004088:0.009483:0.009483:0.009483:0.009483:0.006454:0.006973:0.009483:0.009483:0.009483:0.009483:0.009483:0.006848:0.009483:0.009483:0.009483:0.006848:0.009483:0.009483:0.009483:0.009483:0.006848:0.009476:0.004088
43.  Alexandrov, L. B. :@0.117647:0.325505:0.288784:0.325505:0.288784:0.306984:0.117647:0.306984:0.009483:0.009483:0.004088:0.003735:0.010563:0.013696:0.004711:0.008280:0.009172:0.008259:0.010542:0.010355:0.006765:0.009878:0.007367:0.004088:0.003619:0.010563:0.004088:0.003621:0.010957:0.004088:0.003735
et al.:@0.288668:0.325505:0.323676:0.325505:0.323676:0.306793:0.288668:0.306793:0.007346:0.005727:0.003694:0.009048:0.004607:0.004586
 The repertoire of mutational signatures in human cancer. Nature 578, :@0.323682:0.325505:0.856679:0.325505:0.856679:0.306984:0.323682:0.306984:0.003621:0.010428:0.010282:0.008218:0.003619:0.006765:0.008301:0.010459:0.008218:0.007242:0.005644:0.009857:0.005105:0.006765:0.008218:0.003619:0.009857:0.005644:0.003621:0.015709:0.010065:0.005956:0.008010:0.005852:0.005043:0.009857:0.010625:0.008550:0.004773:0.003619:0.006910:0.005105:0.008965:0.010625:0.008010:0.005603:0.010376:0.006765:0.008218:0.006973:0.003621:0.005105:0.010687:0.003621:0.010085:0.010376:0.015979:0.008259:0.010687:0.003619:0.008280:0.008259:0.010544:0.008176:0.008218:0.005684:0.004088:0.003621:0.014132:0.008010:0.005603:0.010376:0.006765:0.008218:0.003621:0.009483:0.009483:0.009483:0.004088:0.003735
94–101 (2020).:@0.155000:0.346084:0.271520:0.346084:0.271520:0.327563:0.155000:0.327563:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
44.  Van Allen, E. M. :@0.117647:0.366663:0.289553:0.366663:0.289553:0.348142:0.117647:0.348142:0.009483:0.009483:0.004088:0.003735:0.010563:0.011704:0.008259:0.010687:0.005624:0.013696:0.004897:0.004711:0.008218:0.010687:0.004088:0.005624:0.010998:0.004088:0.005624:0.017826:0.004088:0.003735
et al.:@0.291413:0.366663:0.328476:0.366663:0.328476:0.347951:0.291413:0.347951:0.007346:0.005727:0.005748:0.009048:0.004607:0.004586
 Genomic correlates of response to CTLA-4 blockade in metastatic :@0.328468:0.366663:0.856742:0.366663:0.856742:0.348142:0.328468:0.348142:0.005624:0.014381:0.008218:0.010542:0.009857:0.016041:0.005043:0.008176:0.005624:0.008176:0.009857:0.007097:0.006765:0.008135:0.004939:0.008010:0.005644:0.008218:0.006973:0.005624:0.009857:0.005644:0.005624:0.006765:0.008218:0.006827:0.010459:0.009857:0.010563:0.007159:0.008218:0.005624:0.005644:0.010044:0.005624:0.013343:0.012140:0.010708:0.012368:0.006848:0.009483:0.005624:0.009919:0.004711:0.010251:0.007969:0.009650:0.008446:0.010293:0.008218:0.005624:0.005105:0.010687:0.005624:0.015896:0.008301:0.005956:0.008446:0.006827:0.005956:0.008010:0.005852:0.005043:0.008176:0.003735
melanoma. Science 350, 207–211 (2015).:@0.155000:0.387241:0.468889:0.387241:0.468889:0.368720:0.155000:0.368720:0.015896:0.008135:0.004939:0.008259:0.010542:0.009857:0.015979:0.008446:0.004088:0.003735:0.009629:0.008176:0.005043:0.008218:0.010542:0.008176:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
45.  Le, D. T. :@0.117647:0.407820:0.222142:0.407820:0.222142:0.389299:0.117647:0.389299:0.009483:0.009483:0.004088:0.003735:0.010563:0.010749:0.007948:0.004088:0.004368:0.013738:0.004088:0.004379:0.009961:0.004088:0.003735
et al.:@0.222768:0.407820:0.258544:0.407820:0.258544:0.389108:0.222768:0.389108:0.007346:0.005727:0.004462:0.009048:0.004607:0.004586
 Mismatch repair deficiency predicts response of solid tumors to PD-1 block-:@0.258548:0.407820:0.852941:0.407820:0.852941:0.389299:0.258548:0.389299:0.004379:0.017660:0.005105:0.006910:0.015979:0.008010:0.005644:0.007969:0.010417:0.004379:0.006765:0.008301:0.010332:0.008259:0.005105:0.007097:0.004379:0.010293:0.008218:0.005167:0.005105:0.008176:0.005043:0.008218:0.010542:0.008529:0.008840:0.004379:0.010065:0.006765:0.008280:0.010355:0.005041:0.008280:0.005852:0.006973:0.004379:0.006765:0.008218:0.006827:0.010459:0.009857:0.010563:0.007159:0.008218:0.004368:0.009857:0.005644:0.004379:0.007159:0.009940:0.004773:0.005043:0.010355:0.004368:0.005605:0.010376:0.015896:0.009857:0.006931:0.006973:0.004368:0.005647:0.010044:0.004368:0.010604:0.014671:0.006848:0.009483:0.004379:0.009917:0.004711:0.010251:0.007969:0.009510:0.006848
ade. Science 357, 409–413 (2017).:@0.155000:0.428399:0.413524:0.428399:0.413524:0.409878:0.155000:0.409878:0.008446:0.010293:0.007948:0.004088:0.003735:0.009629:0.008176:0.005043:0.008218:0.010542:0.008176:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
46.  Robson, M., Goessl, C. & Domchek, S. Olaparib for Metastatic Germline BRCA-Mutated :@0.117647:0.448977:0.856755:0.448977:0.856755:0.430456:0.117647:0.430456:0.009483:0.009483:0.004088:0.003735:0.010563:0.012451:0.009961:0.009940:0.007159:0.009857:0.010687:0.004088:0.005520:0.017826:0.004088:0.004088:0.005520:0.014381:0.010251:0.008218:0.006846:0.006871:0.004524:0.004088:0.005520:0.013343:0.004088:0.005520:0.014298:0.005520:0.014754:0.009857:0.015896:0.007971:0.010272:0.008135:0.009566:0.004088:0.005520:0.009193:0.004088:0.005520:0.014754:0.004939:0.008010:0.010332:0.008261:0.007097:0.005043:0.010023:0.005520:0.005478:0.009857:0.007097:0.005520:0.017245:0.008301:0.005956:0.008446:0.006827:0.005954:0.008012:0.005852:0.005041:0.008176:0.005520:0.014381:0.008218:0.007097:0.016145:0.004773:0.005105:0.010542:0.008218:0.005520:0.011328:0.012098:0.013343:0.012368:0.006848:0.016954:0.010065:0.005956:0.008010:0.005644:0.008280:0.010355:0.003735
Breast Cancer. The New England journal of medicine vol. 377 1792–1793 (2017).:@0.155000:0.469556:0.772025:0.469556:0.772025:0.451035:0.155000:0.451035:0.011351:0.006765:0.008446:0.008446:0.006827:0.005852:0.003735:0.013613:0.008259:0.010542:0.008176:0.008218:0.005686:0.004088:0.003735:0.010428:0.010282:0.008218:0.003735:0.014111:0.008485:0.013385:0.003735:0.010998:0.010417:0.009027:0.004939:0.008259:0.010542:0.010355:0.003735:0.004856:0.009836:0.010376:0.007097:0.010625:0.008550:0.004773:0.003735:0.009857:0.005644:0.003735:0.015896:0.008280:0.010355:0.005041:0.008176:0.005105:0.010542:0.008218:0.003735:0.008757:0.009940:0.004524:0.004088:0.003735:0.009483:0.009483:0.009483:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
47.  van der Velden, D. L. :@0.117647:0.490135:0.323586:0.490135:0.323586:0.471614:0.117647:0.471614:0.009483:0.009483:0.004088:0.003735:0.010563:0.008944:0.008259:0.010687:0.005292:0.010293:0.008218:0.007097:0.005292:0.011579:0.008135:0.004711:0.010293:0.008218:0.010687:0.004088:0.005292:0.013738:0.004088:0.005292:0.010563:0.004088:0.003735
et al.:@0.325119:0.490135:0.361829:0.490135:0.361829:0.471423:0.325119:0.471423:0.007346:0.005727:0.005395:0.009048:0.004607:0.004586
 The Drug Rediscovery protocol facilitates the expanded use of :@0.361837:0.490135:0.856722:0.490135:0.856722:0.471614:0.361837:0.471614:0.005292:0.010428:0.010282:0.008218:0.005292:0.014568:0.007242:0.010376:0.008965:0.005292:0.012451:0.008280:0.010355:0.005105:0.007159:0.008176:0.009878:0.008757:0.008218:0.007637:0.008840:0.005292:0.010065:0.006765:0.009836:0.005644:0.010251:0.008176:0.009940:0.004773:0.005292:0.005644:0.008446:0.008176:0.005229:0.004773:0.004794:0.005954:0.008012:0.005644:0.008218:0.006973:0.005292:0.006018:0.010272:0.008218:0.005292:0.008280:0.009172:0.010334:0.008259:0.010542:0.010293:0.008280:0.010355:0.005292:0.010376:0.007157:0.008218:0.005292:0.009859:0.005644:0.003735
existing anticancer drugs. Nature 574, 127–131 (2019).:@0.155000:0.510713:0.572998:0.510713:0.572998:0.492193:0.155000:0.492193:0.008280:0.009172:0.005105:0.006827:0.005852:0.005105:0.010417:0.008965:0.003735:0.008259:0.010355:0.005852:0.005043:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.010355:0.007240:0.010376:0.008840:0.006973:0.004088:0.003735:0.014132:0.008010:0.005603:0.010376:0.006765:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
48.  Garraway, L. A. & Jänne, P. A. Circumventing cancer drug resistance in the era of personal-:@0.117647:0.531292:0.852941:0.531292:0.852941:0.512771:0.117647:0.512771:0.009483:0.009483:0.004088:0.003735:0.010563:0.014360:0.008259:0.007097:0.007180:0.008114:0.013385:0.008114:0.007263:0.004088:0.004254:0.010563:0.004088:0.004254:0.013572:0.004088:0.004254:0.014298:0.004254:0.005561:0.008259:0.010687:0.010542:0.007948:0.004088:0.004254:0.008008:0.004088:0.004254:0.013572:0.004088:0.004254:0.013281:0.005105:0.006765:0.008280:0.010376:0.015688:0.008757:0.008218:0.010355:0.005852:0.005105:0.010417:0.008965:0.004254:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.004254:0.010355:0.007242:0.010376:0.008965:0.004254:0.006765:0.008218:0.006910:0.005105:0.006827:0.005954:0.008261:0.010542:0.008176:0.008218:0.004254:0.005105:0.010687:0.004254:0.006018:0.010272:0.008218:0.004254:0.008218:0.007180:0.008446:0.004254:0.009857:0.005644:0.004254:0.010459:0.008218:0.006931:0.007159:0.009857:0.010625:0.008550:0.004881:0.006848
ized medicine. Cancer Discov. 2, 214–226 (2012).:@0.155000:0.551871:0.532698:0.551871:0.532698:0.533350:0.155000:0.533350:0.005105:0.008031:0.008280:0.010355:0.003735:0.015896:0.008278:0.010355:0.005043:0.008176:0.005105:0.010542:0.007948:0.004088:0.003735:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.014568:0.005105:0.007159:0.008176:0.009878:0.007367:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
49.  Ott, P. A. :@0.117647:0.572450:0.228129:0.572450:0.228129:0.553929:0.117647:0.553929:0.009483:0.009483:0.004088:0.003735:0.010563:0.015003:0.005603:0.005852:0.004088:0.004545:0.008010:0.004088:0.004545:0.013572:0.004088:0.003735
et al.:@0.228930:0.572450:0.264892:0.572450:0.264892:0.553738:0.228930:0.553738:0.007346:0.005727:0.004648:0.009048:0.004607:0.004586
 An immunogenic personal neoantigen vaccine for patients with melanoma. :@0.264886:0.572450:0.856703:0.572450:0.856703:0.553929:0.264886:0.553929:0.004545:0.013572:0.010687:0.004545:0.005105:0.016041:0.015709:0.010376:0.010542:0.010044:0.008778:0.008218:0.010687:0.005043:0.008176:0.004545:0.010459:0.008218:0.006931:0.007159:0.009857:0.010625:0.008550:0.004773:0.004545:0.010542:0.008280:0.010127:0.008259:0.010355:0.005852:0.005105:0.008778:0.008218:0.010687:0.004545:0.008944:0.008446:0.008176:0.008176:0.005105:0.010542:0.008218:0.004545:0.005478:0.009857:0.007097:0.004545:0.010334:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006973:0.004545:0.013385:0.004794:0.006018:0.010417:0.004545:0.015898:0.008135:0.004939:0.008259:0.010542:0.009857:0.015979:0.008446:0.004088:0.003735
Nature 547, 217–221 (2017).:@0.155000:0.593028:0.374116:0.593028:0.374116:0.574507:0.155000:0.574507:0.014132:0.008010:0.005603:0.010376:0.006765:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
50.  Fritsch, E. F., Hacohen, N. & Wu, C. J. Personal neoantigen cancer vaccines: The momentum :@0.117647:0.613607:0.856697:0.613607:0.856697:0.595086:0.117647:0.595086:0.009483:0.009483:0.004088:0.003735:0.010563:0.009774:0.007097:0.004794:0.005852:0.007159:0.007969:0.010417:0.004088:0.003652:0.010998:0.004088:0.003652:0.007906:0.004088:0.004088:0.003652:0.014713:0.008446:0.008176:0.009940:0.010274:0.008218:0.010687:0.004088:0.003652:0.014754:0.004088:0.003652:0.014298:0.003652:0.017120:0.010127:0.004088:0.003652:0.013343:0.004088:0.003652:0.005105:0.004088:0.003652:0.010148:0.008218:0.006931:0.007159:0.009855:0.010627:0.008550:0.004773:0.003652:0.010542:0.008280:0.010127:0.008259:0.010355:0.005852:0.005105:0.008778:0.008218:0.010687:0.003652:0.008280:0.008259:0.010542:0.008176:0.008218:0.007097:0.003652:0.008944:0.008446:0.008176:0.008176:0.005105:0.010540:0.008218:0.006973:0.004088:0.003652:0.010428:0.010282:0.008218:0.003652:0.015896:0.009857:0.015896:0.008218:0.010355:0.005605:0.010376:0.016041:0.003735
builds. Oncoimmunology 3, e29311 (2014).:@0.155000:0.634186:0.489620:0.634186:0.489620:0.615665:0.155000:0.615665:0.009816:0.010376:0.005229:0.004711:0.010355:0.006973:0.004088:0.003735:0.014817:0.010542:0.008176:0.009857:0.005105:0.016041:0.015709:0.010376:0.010542:0.009940:0.004711:0.010044:0.009587:0.008840:0.003735:0.009483:0.004088:0.003735:0.008218:0.009483:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
51.  Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of :@0.117647:0.654764:0.856799:0.654764:0.856799:0.636244:0.117647:0.636244:0.009483:0.009483:0.004088:0.003735:0.010563:0.014734:0.008218:0.004794:0.005914:0.008031:0.008218:0.005686:0.004088:0.003300:0.010998:0.004088:0.004088:0.003300:0.014713:0.008446:0.009730:0.010316:0.007948:0.004088:0.003300:0.006599:0.004088:0.003300:0.009193:0.004088:0.004088:0.003300:0.012451:0.009961:0.010231:0.008218:0.007242:0.005852:0.006973:0.004088:0.003300:0.013343:0.004088:0.003300:0.010998:0.004088:0.003300:0.009193:0.004088:0.003300:0.014298:0.003300:0.008905:0.010457:0.008218:0.005043:0.007969:0.010272:0.008218:0.005686:0.004088:0.003300:0.017826:0.004088:0.003300:0.012451:0.004088:0.003300:0.012970:0.010376:0.007097:0.006765:0.008218:0.010355:0.005852:0.003300:0.008259:0.010542:0.010355:0.003300:0.005790:0.010065:0.005603:0.010376:0.006765:0.008218:0.003300:0.010459:0.008218:0.006931:0.006827:0.010459:0.008280:0.008278:0.005852:0.005043:0.008759:0.008218:0.006973:0.003300:0.009857:0.005644:0.003735
liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71–88 (2019).:@0.155000:0.675343:0.762541:0.675343:0.762541:0.656822:0.155000:0.656822:0.004773:0.005043:0.009733:0.010376:0.005043:0.010355:0.003735:0.009836:0.005043:0.009836:0.010166:0.006912:0.005043:0.008218:0.006973:0.003735:0.005105:0.010687:0.003735:0.008776:0.008218:0.010542:0.009857:0.016041:0.005043:0.008176:0.006973:0.006848:0.010355:0.007097:0.005043:0.008757:0.008218:0.010687:0.003735:0.009857:0.010542:0.008176:0.009940:0.004711:0.010044:0.009587:0.007263:0.004088:0.003735:0.014132:0.008010:0.005852:0.004088:0.003735:0.012451:0.008487:0.007367:0.004088:0.003735:0.014379:0.008218:0.010542:0.008301:0.005852:0.004088:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.010729:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
52.  Wan, J. C. M. :@0.117647:0.695922:0.261809:0.695922:0.261809:0.677401:0.117647:0.677401:0.009483:0.009483:0.004088:0.003735:0.010563:0.017079:0.008259:0.010687:0.004088:0.004814:0.005105:0.004088:0.004804:0.013343:0.004088:0.004804:0.017826:0.004088:0.003735
et al.:@0.262870:0.695922:0.299102:0.695922:0.299102:0.677210:0.262870:0.677210:0.007346:0.005727:0.004918:0.009048:0.004607:0.004586
 Liquid biopsies come of age: towards implementation of circulating tu-:@0.299095:0.695922:0.852941:0.695922:0.852941:0.677401:0.299095:0.677401:0.004804:0.010666:0.005043:0.009733:0.010376:0.005043:0.010355:0.004804:0.009836:0.005043:0.009836:0.010168:0.006910:0.005043:0.008218:0.006973:0.004814:0.008176:0.009857:0.015896:0.008218:0.004804:0.009857:0.005644:0.004804:0.008363:0.008778:0.008218:0.004088:0.004814:0.005644:0.009878:0.013385:0.008259:0.006765:0.010355:0.006973:0.004804:0.005105:0.015709:0.010148:0.004711:0.008218:0.015896:0.008218:0.010355:0.005956:0.008010:0.005852:0.005043:0.009857:0.010687:0.004804:0.009857:0.005644:0.004814:0.008176:0.005105:0.006765:0.008280:0.010498:0.004939:0.008010:0.005852:0.005105:0.010417:0.008965:0.004814:0.005603:0.010343:0.006848
mour DNA. Nat. Rev. Cancer 17, 223–238 (2017).:@0.155000:0.716500:0.536060:0.716500:0.536060:0.697980:0.155000:0.697980:0.015896:0.009836:0.010376:0.007097:0.003735:0.014339:0.014007:0.013572:0.004088:0.003735:0.014132:0.008010:0.005852:0.004088:0.003735:0.012449:0.008487:0.007367:0.004088:0.003735:0.013613:0.008259:0.010542:0.008176:0.008218:0.007097:0.003735:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
53.  Cohen, J. D. :@0.117647:0.737079:0.249482:0.737079:0.249482:0.718558:0.117647:0.718558:0.009483:0.009483:0.004088:0.003735:0.010563:0.013634:0.009940:0.010272:0.008218:0.010687:0.004088:0.003445:0.005105:0.004088:0.003445:0.013738:0.004088:0.003735
et al.:@0.249203:0.737079:0.284045:0.737079:0.284045:0.718367:0.249203:0.718367:0.007346:0.005727:0.003528:0.009048:0.004607:0.004586
 Detection and localization of surgically resectable cancers with a multi-an-:@0.284041:0.737079:0.852941:0.737079:0.852941:0.718558:0.284041:0.718558:0.003445:0.014754:0.008301:0.005644:0.008280:0.008280:0.005852:0.005043:0.009857:0.010687:0.003445:0.008259:0.010542:0.010355:0.003445:0.004711:0.010251:0.008280:0.008548:0.004773:0.005105:0.008031:0.008010:0.005852:0.005043:0.009857:0.010687:0.003445:0.009857:0.005644:0.003445:0.006827:0.010376:0.006931:0.008965:0.005043:0.008280:0.008550:0.004897:0.004711:0.008840:0.003445:0.006765:0.008218:0.007159:0.008280:0.008278:0.005956:0.008280:0.009919:0.004711:0.008218:0.003445:0.008280:0.008259:0.010542:0.008176:0.008218:0.006931:0.006973:0.003445:0.013385:0.004794:0.006018:0.010417:0.003445:0.008446:0.003445:0.015709:0.010500:0.004462:0.005852:0.005105:0.006848:0.008259:0.010727:0.006848
alyte blood test. Science 359, 926–930 (2018).:@0.155000:0.757658:0.502297:0.757658:0.502297:0.739137:0.155000:0.739137:0.008550:0.004711:0.008840:0.005644:0.008218:0.003735:0.009919:0.004711:0.010251:0.010251:0.010355:0.003735:0.005642:0.008218:0.006829:0.005852:0.004088:0.003735:0.009627:0.008176:0.005043:0.008218:0.010542:0.008176:0.008218:0.003735:0.009483:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
54.  Diehl, F. :@0.117647:0.778237:0.222785:0.778237:0.222785:0.759716:0.117647:0.759716:0.009483:0.009483:0.004088:0.003735:0.010563:0.014568:0.005043:0.008135:0.010521:0.004524:0.004088:0.005175:0.007908:0.004088:0.003735
et al.:@0.224226:0.778237:0.260832:0.778237:0.260832:0.759525:0.224226:0.759525:0.007346:0.005727:0.005292:0.009048:0.004607:0.004586
 Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985–990 :@0.260832:0.778237:0.856677:0.778237:0.856677:0.759716:0.260832:0.759716:0.005178:0.013281:0.005105:0.006765:0.008280:0.010498:0.004939:0.008010:0.005852:0.005105:0.010417:0.008965:0.005178:0.015709:0.010065:0.005956:0.008259:0.010355:0.005852:0.005178:0.014339:0.014007:0.013572:0.005178:0.005644:0.010044:0.005178:0.008446:0.006846:0.007159:0.008218:0.006848:0.006973:0.005178:0.005603:0.010376:0.015896:0.009857:0.007097:0.005178:0.010293:0.008840:0.010625:0.008259:0.016041:0.005043:0.008176:0.006973:0.004088:0.005178:0.014132:0.008010:0.005852:0.004088:0.005178:0.017245:0.008278:0.010106:0.004088:0.005178:0.009483:0.009483:0.004088:0.005178:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.003735
(2008).:@0.155000:0.798815:0.209639:0.798815:0.209639:0.780294:0.155000:0.780294:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
55.  Leary, R. J. :@0.117647:0.819394:0.240123:0.819394:0.240123:0.800873:0.117647:0.800873:0.009483:0.009483:0.004088:0.003735:0.010563:0.010749:0.008446:0.008259:0.007635:0.007265:0.004088:0.004607:0.012451:0.004088:0.004607:0.005105:0.004088:0.003735
et al.:@0.240973:0.819394:0.276997:0.819394:0.276997:0.800682:0.240973:0.800682:0.007346:0.005727:0.004711:0.009048:0.004607:0.004586
 Detection of chromosomal alterations in the circulation of cancer patients :@0.276988:0.819394:0.856745:0.819394:0.856745:0.800873:0.276988:0.800873:0.004607:0.014754:0.008299:0.005644:0.008280:0.008280:0.005852:0.005043:0.009857:0.010687:0.004607:0.009857:0.005644:0.004607:0.007971:0.010417:0.006763:0.009859:0.015896:0.009961:0.007159:0.009855:0.015981:0.008550:0.004773:0.004607:0.008550:0.004462:0.005644:0.008218:0.007180:0.008010:0.005852:0.005043:0.009857:0.010563:0.006973:0.004607:0.005105:0.010687:0.004607:0.006018:0.010272:0.008218:0.004607:0.008176:0.005105:0.006765:0.008280:0.010498:0.004939:0.008010:0.005852:0.005043:0.009857:0.010687:0.004607:0.009857:0.005644:0.004607:0.008278:0.008261:0.010542:0.008176:0.008218:0.007097:0.004607:0.010334:0.008010:0.005852:0.005043:0.008218:0.010355:0.005852:0.006973:0.003735
with whole-genome sequencing. Sci. Transl. Med. 4, 162ra154 (2012).:@0.155000:0.839973:0.684162:0.839973:0.684162:0.821452:0.155000:0.821452:0.013385:0.004794:0.006018:0.010417:0.003735:0.013445:0.010274:0.009940:0.004711:0.008218:0.006848:0.008776:0.008218:0.010544:0.009857:0.015896:0.008218:0.003735:0.007157:0.008280:0.009733:0.010314:0.008218:0.010542:0.008176:0.005105:0.010417:0.008799:0.004088:0.003735:0.009629:0.008176:0.004856:0.004088:0.003735:0.010210:0.007180:0.008259:0.010563:0.006869:0.004524:0.004088:0.003735:0.017245:0.008280:0.010106:0.004088:0.003735:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.007178:0.008446:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088
56.  Mattos-Arruda, L. D. :@0.117647:0.860551:0.322507:0.860551:0.322507:0.842031:0.117647:0.842031:0.009483:0.009483:0.004088:0.003735:0.010563:0.017348:0.008010:0.005603:0.005644:0.009961:0.006973:0.006848:0.013572:0.007097:0.007242:0.010314:0.010521:0.008446:0.004088:0.004814:0.010563:0.004088:0.004814:0.013738:0.004088:0.003735
et al.:@0.323564:0.860551:0.359796:0.860551:0.359796:0.841839:0.323564:0.841839:0.007346:0.005727:0.004918:0.009048:0.004607:0.004586
 Capturing intra-tumor genetic heterogeneity by de novo muta-:@0.359792:0.860551:0.852941:0.860551:0.852941:0.842031:0.359792:0.842031:0.004814:0.013613:0.008010:0.010042:0.005605:0.010376:0.007097:0.005105:0.010415:0.008965:0.004814:0.005105:0.010355:0.005852:0.007180:0.008446:0.006848:0.005603:0.010376:0.015896:0.009857:0.007097:0.004814:0.008778:0.008218:0.010542:0.008301:0.005852:0.005043:0.008176:0.004814:0.010274:0.008301:0.005644:0.008218:0.006765:0.010044:0.008778:0.008218:0.010542:0.008218:0.004794:0.005852:0.008840:0.004814:0.009857:0.008840:0.004814:0.010293:0.008218:0.004814:0.010542:0.009878:0.008757:0.010044:0.004814:0.015709:0.010062:0.005956:0.008393:0.006848
tion profiling of circulating cell-free tumor DNA: a proof-of-principle. Annals of Oncology :@0.155000:0.881130:0.856610:0.881130:0.856610:0.862609:0.155000:0.862609:0.005852:0.005043:0.009857:0.010687:0.004130:0.010065:0.006765:0.009857:0.005167:0.005292:0.004773:0.005105:0.010417:0.008965:0.004130:0.009857:0.005644:0.004130:0.008176:0.005105:0.006765:0.008280:0.010500:0.004937:0.008012:0.005852:0.005105:0.010417:0.008965:0.004130:0.008176:0.008135:0.004897:0.004773:0.006848:0.005831:0.006765:0.008280:0.008218:0.004130:0.005603:0.010376:0.015896:0.009857:0.007097:0.004130:0.014339:0.014007:0.013572:0.004088:0.004130:0.008446:0.004130:0.010065:0.006765:0.010251:0.009857:0.005644:0.006848:0.009857:0.005644:0.006848:0.010062:0.007097:0.005105:0.010542:0.008176:0.004794:0.010148:0.004711:0.007948:0.004088:0.004130:0.013572:0.010687:0.010625:0.008550:0.004773:0.006973:0.004130:0.009857:0.005644:0.004130:0.014817:0.010542:0.008176:0.009940:0.004711:0.010044:0.009587:0.008840:0.003735
25, 1729–1735 (2014).:@0.155000:0.901709:0.326761:0.901709:0.326761:0.883188:0.155000:0.883188:0.009483:0.009483:0.004088:0.003735:0.009483:0.009483:0.009483:0.009483:0.010729:0.009483:0.009483:0.009483:0.009483:0.003735:0.006308:0.009483:0.009483:0.009483:0.009483:0.006308:0.004088